RECENT NEWS

Biotia has announced a joint development agreement with Mayo Clinic to propel precision medicine in infectious disease diagnostics.

The British In Vitro Diagnostics Association (BIVDA) - along with leading industry and health charities - has launched a new policy declaration that highlights the value of community diagnostics and their role in a future neighbourhood NHS.

Digital pathology firm Diagnexia and Stratipath AB, a pioneer in AI-based cancer diagnostics, have announced a strategic partnership to bring Stratipath Breast, an AI-based prognostic risk profiling tool for invasive breast cancer, to pathology laboratories, hospitals, and healthcare providers across the UK and Europe.

The Association for Molecular Pathology and pathologist Michael Laposata MD PhD, have announced a favourable ruling in their lawsuit against the U.S. Food and Drug Administration over the regulation of laboratory-developed test (LDT) procedures.

The National Cancer Institute (NCI), part of the U.S. National Institutes of Health (NIH), is to partner with cancer diagnostics firm Lunit to explore innovative applications of AI in cancer research.

The Medicines and Healthcare products Regulatory Agency (MHRA) recently hosted an event for the seven newly established Centres of Excellence in Regulatory Science and Innovation (CERSIs) to showcase how their projects will help drive advancements in healthcare.

Richard Hames, General Manager of Werfen UK, has been elected Chair of the British In Vitro Diagnostics Association (BIVDA).

New data from the UK Health Security Agency (UKHSA) show that last year imported dengue cases in England, Wales and Northern Ireland (EWNI) reached their highest level since dengue surveillance began in 2009. All cases are linked to travel abroad.

Thornhill Healthcare Events' 10th face-to-face event will see the main topic of discussion be the government's forthcoming 10-year plan and the part clinical innovations will play in delivering improved patient care and true service transformation.

Digital pathology service provider Diagnexia has launched a Global Education and Outreach Programme, a transformative initiative aimed at enhancing education, diagnostic access and healthcare outcomes in regions with limited pathology resources.

Citylabs 4.0, a new £42million specialist laboratory and office space, is now officially open at Manchester University NHS Foundation Trust’s (MFT) Oxford Road hospital campus, in a further boost to the city’s position as a leading hub for health innovation.

Royal Philips has announced the expansion of its partnership with Ibex Medical Analytics and a new release of Philips IntelliSite Pathology Solution to further accelerate the adoption of AI-enabled digital pathology.

Digital pathology firm Techcyte has launched Fusion, its first open, standards-based, SaaS platform designed to unify anatomic and clinical pathology workflows.

A new Priority Pathogens reference tool aims to support national funders of research and development into diagnostics, vaccines and therapeutics.

A newly announced partnership will see Pictor Labs' ReStain virtual staining technology integrated directly into Pramana’s advanced SpectralHT scanners.

Chicago-based healthcare system Northwestern Medicine has entered into a new collaboration with Vitestro, which will include testing of Vitestro's autonomous robotic phlebotomy device Aletta.

Digital pathology firm Gestalt, and Primaa, a MedTech pioneer specialising in AI-based dermatopathology solutions, have announced a strategic partnership.

Diagnexia has announced an exclusive partnership with Artera to bring the ArteraAI Prostate Biopsy Assay to the UK.

The IBMS and global innovation consultancy PA Consulting have released the second paper in the ‘Earlier Diagnostics’ series, offering a strategic blueprint for optimising UK diagnostic services.

Revvity has expanded its alliance with Genomics England to further collaborate on the Generation Study. Under the new contract, Revvity will now also provide DNA sequencing services to help screen newborns for rare genetic conditions.